Paraoxonase activity in patients with erectile dysfunction

International Journal of Impotence Research

Volumn 19, Issue 5, 2007, Pages 517-520

  Ciftci, H ^a   Yeni, E ^a   Savas, M ^a   Verit, A ^a   Celik, H ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Erectile dysfunction; Paraoxonase; Risk factor

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; HUMAN; LIPID BLOOD LEVEL; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PEROXIDATION; PRIORITY JOURNAL; RISK FACTOR; SPECTROFLUOROMETRY; STATISTICAL ANALYSIS; STUDENT T TEST;

ADULT; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED;

EID: 34548379143     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901565     Document Type: Article

References (27)

1. Simonsen U, Garcia-Sacristan A, Prieto D. Penile arteries and erection. J Vasc Res 2002; 39: 283-303.
2. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-154.
3. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 275: 17527-17535.
4. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-2891.
5. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995; 95: 774-782.
6. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004; 37: 1304-1316.
7. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic Biol Med 2004; 37: 1317-1323.
8. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD et al. Furlong CE Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000; 20: 2441-2447.
9. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107: 2775-2779.
10. Sarandol A, Sarandol E, Eker SS, Karaagac EU, Hizli BZ, Dirican M et al. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1103-1108.
11. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 330-335.
12. Mc Elveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolysing activity in the serum of patients after myocardial infarction. Clin Chem 1986; 32: 671-673.
13. Isik A, Koca SS, Ustundag B, Celik H, Yildirim A Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin Rheumatol 2007; 26: 342-348.
14. Martin-Morales AM, Sanchez-Cruz JJ, Saenz de Tejeda I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalance and independent risk factors for erectile dysfunction in spain: result of the epidemiologia de la disfunction erectil masculina study. J Urol 2001; 166: 569-574.
15. Nusbaum MR. Erectile dysfunction: prevalence, etiology and major risk factor. J Am Osteopath Assoc 2002; 102: 1-6.
16. Morley JE, Kaiser FE. Impotence in elderly men. Drugs Aging 1992; 2: 330-344.
17. Michal V. Arterial disease as a cause of impotence. Clin Endocrinol Metab 1982; 11: 725-748.
18. Yesilli C, Yaman O, Anafarta K. Effect of experimental hypercholesterolemia on cavernozal structers. Urology 2001; 57: 1184-1188.
19. Azadzoi KM, Seanz de Tjeda I. Hypercollesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 1991; 146: 238-240.
20. Ahn TY, Gomez-Coronado D, Martinez V. Enhanced contractility of rabbit corpus cavernosum smooth muscle by oxidized low density lipoproteins. Int J impot Res 1999; 11: 9-14.
21. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173: 1-12.
22. Gordon DJ, Probstfeld JL, Garrison RJ. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American study. Circulation 1989; 37: 47-53.
23. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998; 31: 329-336.
24. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473-480.
25. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler Suppl 2002; 3: 49-55.
26. Aviram M. Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today 1999; 5: 381-386.
27. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590.